Do Annual Checkups Actually Help You Live Longer?

Here's the resolution to the "do annual physicals save lives?" debate that more people should hear up front: the visit is the vehicle, not the treatment.

The contrarian take you've probably encountered (usually backed by a Cochrane review of "general health checks") is that a generic annual physical doesn't measurably reduce mortality. That's true, and it's also misleading, because the physical itself isn't doing the work. The specific screenings scheduled during those visits are. And the evidence for those screenings is some of the strongest in medicine.

When we were weighting preventive care in Longlevity, this was the distinction we had to think hardest about. Treating "had a physical this year" as the input understates the effect; treating individual screenings as independent inputs double-counts them. What actually matters is whether someone is in an active screening pipeline, attached to a primary care relationship that schedules age-appropriate tests and follows up on anything abnormal.

A striking single data point: the National Polyp Study, followed for 15.8 years, found that removing precancerous polyps during colonoscopy was associated with a 53% lower colorectal cancer death rate versus what the general population would predict (Shaukat et al., NEJM, 2012). That is an eye-catching number, but it compared screened patients to expected population rates rather than to a randomized control group, so it almost certainly runs ahead of the real-world screening effect. The first large randomized trial, NordICC (NEJM, 2022, ~84,000 people), found a more measured picture on an intention-to-screen basis: an 18% drop in colorectal cancer incidence and a roughly 10% reduction in colorectal cancer death that did not reach statistical significance. The honest read across both is that colonoscopy's benefit is real and among the better-evidenced in preventive medicine, just smaller than the headline 53%. And either way, you can't get to the colonoscopy without the visit that referred you to it.

The short answer

• Specific screenings have strong mortality-reduction evidence: colonoscopy, mammography, blood pressure control, cholesterol management, diabetes screening
• The generic annual physical has weaker evidence, but it's the delivery mechanism for the specific screenings that do work
• Regular engagement with preventive care is associated with meaningfully lower all-cause mortality
• Age-specific screenings matter: USPSTF now recommends colonoscopy starting at 45, mammography at 40
• The highest-leverage screenings: blood pressure, lipid panel, HbA1c, colonoscopy (45+), mammography (40+ with shared decision), skin check if risk factors

Want to see how your preventive care habits are affecting your estimate? Take the Longlevity assessment →

The National Polyp Study, 15.8 years later

The National Polyp Study (NPS) was a landmark U.S. trial that began in 1980 and followed 2,602 patients who had colorectal polyps removed during colonoscopy. Shaukat and colleagues published the long-term mortality results in 2012 after 15.8 years of follow-up, unusually long for a prospective study.

The findings:

• 53% lower colorectal cancer death rate in the screened cohort vs. expected rates based on general population data
• The effect was durable: benefits persisted throughout the 15.8-year follow-up
• The study helped establish colonoscopy as a leading tool for colorectal cancer screening

Colorectal cancer is the second-leading cause of cancer death in the U.S. The catch is study design: the National Polyp Study compared its patients to expected population death rates, not to a randomized control group, so its 53% figure likely overstates the real-world screening effect. When colonoscopy was finally put to a randomized test in the NordICC trial (NEJM, 2022), the intention-to-screen benefit was more modest: roughly an 18% reduction in colorectal cancer incidence and a ~10% reduction in colorectal cancer deaths that did not reach statistical significance. The honest summary is that colonoscopy still sits in the upper tier of preventive interventions, just not at a settled 50%. For comparison, aggressive lipid-lowering therapy typically reduces cardiovascular mortality by 15-25%, and quitting smoking in midlife adds several years.

This is why colonoscopy is still strongly recommended even when its annoyance factor is high. The effect is real and among the better-documented in screening, even if the exact size is now genuinely debated.

What screenings move mortality

Not all "preventive care" is created equal, and this was the part that genuinely shifted how we thought about the topic.

A tight hierarchy of what the evidence supports, strongest to weakest:

The interventions with the biggest mortality signal are the ones you'd expect from the existing data: screening colonoscopy starting at 45 (a large reduction in colorectal cancer mortality in observational data, a smaller but real benefit in the first randomized trial), mammography starting at 40 with shared decision-making (updated by USPSTF in 2024), and, critically, blood pressure screening and treatment, which is probably the single most impactful preventive intervention in all of cardiovascular medicine. Untreated hypertension is a leading cause of stroke and heart failure, and it's silent until it isn't. Cholesterol screening with appropriate statin therapy, HbA1c or fasting glucose for diabetes, and counseling support for smoking cessation all sit in this top tier.

Strong but more context-dependent: cervical cancer screening per current guidelines, skin checks when risk factors are present, DEXA bone density scans in post-menopausal women and older men, and abdominal aortic aneurysm screening in men 65-75 with smoking history. These have real evidence but their value depends on your specific risk profile.

Controversial or lower-yield: prostate cancer screening via PSA (modest mortality benefit, significant overdiagnosis risk, USPSTF recommends shared decision-making for men 55-69), routine EKG in asymptomatic adults (USPSTF explicitly recommends against it), and the full-body MRI that's increasingly marketed direct-to-consumer. The full-body MRI in particular is worth naming: the evidence for mortality benefit in general populations is limited, the false-positive rate is substantial, and the cascade of follow-up testing those false positives trigger often produces net harm.

Near-zero evidence: heavy-metal detox panels, food sensitivity tests, most "functional medicine" labs, and the generic multivitamin marketed as preventive. These are popular and they are not supported by mortality data.

The reframe that resolves the debate

A cleaner way to think about preventive care than "do I need an annual physical?":

Am I in an active screening pipeline? Attached to a primary care provider who's ordering the age-appropriate tests, interpreting results, and following up on anything abnormal.

If yes, the visit is doing its job. If no, you're missing the part of preventive medicine where the evidence is strongest, regardless of whether you've "had a physical this year."

The failure mode isn't typically the initial visit. It's the dropped follow-up: the recheck never scheduled, the referral that slipped off the calendar, the abnormal result that nobody circled back on.

How many actual years?

This is harder to estimate than other lifestyle factors because preventive care's effect is highly heterogeneous: you benefit a lot if you have a condition caught early, and little if you don't. For an average adult engaging with evidence-based preventive care:

• Baseline blood pressure management: ~1-2 years of added life expectancy
• Cholesterol management when indicated: ~6 months to 1 year in at-risk populations
• Colonoscopy at recommended intervals: ~1-2 years of life expectancy gain at population level (but potentially decades for the individual whose cancer is caught early)
• Mammography: similar population-level effects, larger individual impact when cancer is caught early

Aggregate estimates suggest regular, evidence-based preventive care adds roughly 2-3 years of life expectancy for the average adult, concentrated in healthspan rather than extreme old age. The value isn't primarily in finding things in a "great shape" person; it's in catching the hidden conditions that would otherwise become crises.

The highest-leverage change

The principle that cuts through most of the "annual physical" debate: it's not the visit, it's the screening pipeline. And the highest-leverage moves inside that pipeline are unglamorous:

The big four baseline numbers (blood pressure, lipid panel, HbA1c or fasting glucose, and body composition) are cheap, fast, and catch most of the silent conditions that shorten lifespans. A single blood draw gets most of them; frequency depends on your age and risk factors, which is a conversation for your doctor.

The age-triggered cancer screenings are where the research is strongest. The U.S. Preventive Services Task Force (USPSTF) currently recommends colonoscopy starting at 45 (earlier with family history), mammography starting at 40 with shared decision-making (updated in 2024), cervical cancer screening per current guidelines, and skin checks when risk factors are present. Exact timing and method are decisions to make with your primary care provider. This post is describing the pattern the research supports, not prescribing what's right for you specifically.

The single most common failure mode isn't skipping the initial screening. It's skipping the follow-up after a flagged result. A lot of preventable deaths trace to someone missing the second step after a first abnormal lab.

What doesn't work (or works less than people think)

• Routine whole-body MRI for screening. Increasingly marketed to healthy adults. USPSTF and most specialty societies do not support it. High false-positive rate leads to cascades of unnecessary further testing, often with net harm from anxiety, costs, and overtreatment.
• Most "biological age" tests: interesting research tools but most consumer biological age tests (methylation clocks, telomere measurement kits) lack clinical validation for personal health decisions.
• Annual EKG in asymptomatic adults: USPSTF explicitly recommends against routine use in low-risk adults
• Supplements as preventive medicine: multivitamins, specific vitamins (D, C, E) for prevention show mixed-to-weak evidence for mortality benefit in healthy adults
• Self-diagnostic apps without professional backup: useful for tracking, not for diagnosis

The bottom line

The "annual physicals don't save lives" takes are partially right about the visit itself and completely wrong about the screenings delivered. What the research supports is simple:

• Get the big four labs (BP, lipids, glucose, BMI) every 1-3 years
• Age-appropriate cancer screenings at recommended ages
• Basic blood pressure and metabolic management
• A primary care provider who knows your history

Skip them and you're leaving real, preventable risk on the table. Do them and you're in the strongest-evidence category of longevity interventions, right up there with not smoking and regular exercise. Our methodology page walks through exactly how we weight preventive care in the estimate.

Frequently asked questions

Citations

• Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer (National Polyp Study). New England Journal of Medicine. 2012;366(8):687-696.
• Bretthauer M, Løberg M, Wieszczy P, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death (NordICC trial). New England Journal of Medicine. 2022;387(17):1547-1556.
• U.S. Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977.
• Maciosek MV, Coffield AB, Flottemesch TJ, et al. Greater use of preventive services in U.S. health care could save lives at little or no cost. Health Affairs. 2010;29(9):1656-1660.